Target intelligence / Profile preview

Cathelicidin antimicrobial peptide (LL-37)

Target
LL-37
Molecular classification
Antimicrobial peptide, Host defense peptide, Cathelicidin
01

Overview

Cathelicidin antimicrobial peptide (CAMP), specifically its active 37-amino acid C-terminal fragment LL-37, is a vital multifunctional host defense peptide in humans (UniProt P49913). It is primarily expressed by neutrophils and various epithelial cells, where it is stored as the pro-protein hCAP-18 and cleaved upon activation by proteinase 3. LL-37 exhibits potent, broad-spectrum antimicrobial activity by directly disrupting microbial membranes and neutralizing lipopolysaccharides (LPS). Additionally, it functions as a signaling molecule, promoting wound healing, angiogenesis, and the chemotaxis of leukocytes through receptors like Formyl peptide receptor 2 (FPR2). Dysregulation of LL-37 is linked to several pathologies; for instance, its deficiency increases susceptibility to infections in atopic dermatitis, while its overexpression drives auto-inflammatory responses in psoriasis and rosacea. Consequently, LL-37 is a target for therapeutic intervention, with synthetic versions being developed for chronic wound care and inhibitors being explored for autoimmune conditions.

Other names
hCAP-18Human cationic antimicrobial protein 18CAMPFALL-39CAP-1818 kDa cationic antimicrobial protein
02

Mechanism of action

LL-37 functions by directly disrupting microbial cell membranes through pore formation and by binding to host cell receptors, including Formyl peptide receptor 2 (FPR2), P2X7 receptor, and Toll-like receptors, to modulate inflammatory signaling and promote tissue repair.

03

Biological functions

Immune responseAntimicrobial activityChemotaxisWound healingAngiogenesisLPS neutralizationApoptosis regulation
04

Disease associations

InfectionPsoriasisRosaceaAtopic dermatitisSystemic lupus erythematosusSepsisCancerChronic obstructive pulmonary disease
05

Safety considerations

Induction of auto-inflammatory responsesPotential pro-tumorigenic effects in specific cancers (e.g., lung, breast)Risk of systemic inflammatory response syndrome if over-activatedSkin irritation or sensitization in topical applications
06

Interacting drugs

LL-37 (synthetic peptide)

4 more in the full profile.

07

Biomarkers

LL-37 expression levels in skin lesionsSerum LL-37 concentrationhCAP-18 mRNA levels in neutrophils

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Cathelicidin antimicrobial peptide (LL-37).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cathelicidin antimicrobial peptide (LL-37).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call